Pharma

nference said researchers can use the de-identified clinical data to develop new therapeutics and diagnostics.

The company announced a $200 million Series C round in January.

The company said the clearance will allow more pharma companies to use Tasso+ for decentralized clinical trials.

The partnership will allow Withings' connected scales, blood pressure monitors and sleep-tracking mats to integrate with Medable's trial platform.

The toolkits are based on the Digital Medicine Society's Sensor Data Integrations project, which includes organizations like Amazon Web Services, Oracle, the Moffitt Cancer Center, Takeda and the U.S. Department of Veterans Affairs.

The company is leveraging its own portfolio and partner digital assets to directly engage patients at home, virtually or in-person.

The companies said their long-term goal is to develop and offer more digital health tools "through a multi-partner ecosystem" as well as advocate for reimbursement options.

Under the deal, MedRhythms would receive a $3 million upfront payment and could earn up to $117.5 million if certain milestones are met.

The partnership, which includes Anthem, Biogen, Eli Lilly, Evidation, Janssen and Merck, gives payers guidance for including digital endpoints in reimbursement for new drugs.

Abbott's Jennifer Jones-McMeans outlines how finding community champions and creating digital tools can help boost diversity in clinical trials.